** Shares of biotechnology firm Windtree Therapeutics WINT.O rise 27.8% to $2.16 in afternoon trading
** WINT says it has entered into a licensing deal with Evofem Biosciences EVFM.PK for its birth control vaginal gel, Phexxi
** WINT will serve as the sourcing partner to Evofem and aims to produce Phexxi at a cheaper cost
** Co says Evofem will maintain ownership of the asset and continue to commercialize Phexxi in the U.S. and internationally
** Up to last close, WINT has fallen 99.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。